Kymera Therapeutics (KYMR) Stock Statistics & Valuation Metrics

Kymera Therapeutics has a market cap or net worth of $6.45B. The enterprise value is $6.18B.

Kymera Therapeutics has 81,642,395 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kymera Therapeutics’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -20.88%.

The current PE Ratio of Kymera Therapeutics is ―. Kymera Therapeutics’s PEG ratio is -0.89.

In the last 12 months, Kymera Therapeutics had revenue of 39.20M and earned -311.40M in profits. Earnings per share was -3.69.

In the last 12 months, operating cash flow was -232.89M and capital expenditures -1.45M, giving a free cash flow of -234.34M billion.

Kymera Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Kymera Therapeutics upcoming earnings date is Apr 30, 2026, Before Open (Confirmed).

Kymera Therapeutics as a current ratio of 10.47, with Debt / Equity ratio of 5.21%

In the past 12 months, Kymera Therapeutics has paid 0.00 in taxes.

Kymera Therapeutics EV to EBITDA ratio is -20.76, with an EV/FCF ratio of -26.85.

Kymera Therapeutics has $848.28M in cash and marketable securities with $82.25M in debt, giving a net cash position of $766.02M billion.

Gross margin is 100.00%, with operating margin of -891.33%, and net profit margin of -794.39%.

The average price target for Kymera Therapeutics is $121.47, which is 11.43% higher than the current price. The consensus rating is Strong Buy